Format

Send to

Choose Destination
See comment in PubMed Commons below
PLoS One. 2014 Jun 18;9(6):e99272. doi: 10.1371/journal.pone.0099272. eCollection 2014.

Targeting the Wnt/β-catenin signaling pathway in liver cancer stem cells and hepatocellular carcinoma cell lines with FH535.

Author information

1
Department of Surgery, University of Kentucky, Lexington, Kentucky, United States of America.
2
Department of Physiology, University of Kentucky, Lexington, Kentucky United States of America.
3
Department of Microbiology, Immunology & Molecular Genetics, University of Kentucky, Lexington, Kentucky, United States of America; Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States of America.
4
Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States of America.

Abstract

Activation of the Wnt/β-catenin pathway has been observed in at least 1/3 of hepatocellular carcinomas (HCC), and a significant number of these have mutations in the β-catenin gene. Therefore, effective inhibition of this pathway could provide a novel method to treat HCC. The purposed of this study was to determine whether FH535, which was previously shown to block the β-catenin pathway, could inhibit β-catenin activation of target genes and inhibit proliferation of Liver Cancer Stem Cells (LCSC) and HCC cell lines. Using β-catenin responsive reporter genes, our data indicates that FH535 can inhibit target gene activation by endogenous and exogenously expressed β-catenin, including the constitutively active form of β-catenin that contains a Serine37Alanine mutation. Our data also indicate that proliferation of LCSC and HCC lines is inhibited by FH535 in a dose-dependent manner, and that this correlates with a decrease in the percentage of cells in S phase. Finally, we also show that expression of two well-characterized targets of β-catenin, Cyclin D1 and Survivin, is reduced by FH535. Taken together, this data indicates that FH535 has potential therapeutic value in treatment of liver cancer. Importantly, these results suggest that this therapy may be effective at several levels by targeting both HCC and LCSC.

PMID:
24940873
PMCID:
PMC4062395
DOI:
10.1371/journal.pone.0099272
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Public Library of Science Icon for PubMed Central
    Loading ...
    Support Center